title: Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers.
abstract: Currently no pharmacogenomics-based criteria exist to guide clinicians in identifying individuals who are at risk of hearing loss from cisplatin-based chemotherapy. This review summarizes findings from pharmacogenomic studies that report genetic polymorphisms associated with cisplatin-induced hearing loss and aims to (1) provide up-to-date information on new developments in the field, (2) provide recommendations for the use of pharmacogenetic testing in the prevention, assessment, and management of cisplatin-induced hearing loss in children and adults, and (3) identify knowledge gaps to direct and prioritize future research. These practice recommendations for pharmacogenetic testing in the context of cisplatin-induced hearing loss reflect a review and evaluation of recent literature, and are designed to assist clinicians in providing optimal clinical care for patients receiving cisplatin-based chemotherapy.
authors.affiliation: *Center for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada; †Pharmaceutical Outcomes Programme, British Columbia Children's Hospital, Vancouver, British Columbia, Canada; ‡Child and Family Research Institute, Vancouver, British Columbia, Canada; §Department of Pediatrics, Division of Pediatric Hematology/Oncology/Bone Marrow Transplant, British Columbia Children's Hospital, Vancouver, British Columbia, Canada; ¶Department of Medical Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada; ‖Department of Medical Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada; **Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada; ††Division of Translational Therapeutics, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada; and ‡‡Institute of Clinical Chemistry, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland.
authors.forename: Jong W
authors.initials: JW
authors.lastname: Lee
authors.forename: Kusala
authors.initials: K
authors.lastname: Pussegoda
authors.forename: Shahrad R
authors.initials: SR
authors.lastname: Rassekh
authors.forename: Jose G
authors.initials: JG
authors.lastname: Monzon
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Liu
authors.forename: Soomi
authors.initials: S
authors.lastname: Hwang
authors.forename: Amit P
authors.initials: AP
authors.lastname: Bhavsar
authors.forename: Sheila
authors.initials: S
authors.lastname: Pritchard
authors.forename: Colin J
authors.initials: CJ
authors.lastname: Ross
authors.forename: Ursula
authors.initials: U
authors.lastname: Amstutz
authors.forename: Bruce C
authors.initials: BC
authors.lastname: Carleton
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use*; D005819:Genetic Markers / Q000235:genetics*; D034381:Hearing Loss / Q000139:chemically induced* / Q000235:genetics*; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods; D011110:Polymorphism, Genetic / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D005819:Genetic Markers; D002945:Cisplatin